Loss of Sparc in p53-null Astrocytes Promotes Macrophage Activation and Phagocytosis Resulting in Decreased Tumor Size and Tumor Cell Survival

Brain Pathology

Volumn 25, Issue 4, 2015, Pages 391-400

  Thomas, Stacey L ^a   Schultz, Chad R ^a   Mouzon, Ezekiell ^a   Golembieski, William A ^a   Naili, Reima El ^a   Radakrishnan, Archanna ^a   Lemke, Nancy ^a   Poisson, Laila M ^a   Gutiérrez, Jorge A ^b   Cottingham, Sandra ^c   Rempel, Sandra A ^a  

^a HENRY FORD HOSPITAL   (United States)

^b Division of Neurosurgery   (United States)

^c SPECTRUM HEALTH   (United States)

Author keywords

glioblastoma; glioma; immunosuppression; macrophage; microglia; p53; p53 null; SPARC; Sparc null; TP53; xenograft

Indexed keywords

OSTEONECTIN; PROTEIN P53; SPARC PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CANCER INHIBITION; CANCER STAGING; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE DELETION; GENE INDUCTION; GLIOMA; GLIOMA CELL; IMMUNOGENICITY; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LOSS OF FUNCTION MUTATION; MACROPHAGE ACTIVATION; MICROGLIA; MOUSE; NONHUMAN; PHAGOCYTOSIS; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BRAIN CORTEX; BRAIN TUMOR; C57BL MOUSE; CYTOLOGY; DEFICIENCY; GENETICS; GENOTYPE; HUMAN; MACROPHAGE; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; RAT; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; ASTROCYTES; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CEREBRAL CORTEX; GENOTYPE; GLIOMA; HUMANS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; OSTEONECTIN; PHAGOCYTOSIS; RATS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84931571864     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12161     Document Type: Article

References (44)

1. Alvarez MJ, Prada F, Salvatierra E, Bravo AI, Lutzky VP, Carbone C, et al (2005) Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Res 65: 5123-5132.
2. Badie B, Drazan KE, Kramar MH, Shaked A, Black KL, (1995) Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. Neurol Res 17: 209-216.
3. Badie B, Kramar MH, Lau R, Boothman DA, Economou JS, Black KL, (1998) Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors. J Neurooncol 37: 217-222.
4. Badie B, Schartner JM, (2000) Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery 46: 957-961, discussion 61-2.
5. Badie B, Schartner JM, Paul J, Bartley BA, Vorpahl J, Preston JK, (2000) Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. J Neurosurg 93: 634-639.
6. Bogler O, Huang HJ, Cavenee WK, (1995) Loss of wild-type p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation. Cancer Res 55: 2746-2751.
7. Bogler O, Nagane M, Gillis J, Huang HJ, Cavenee WK, (1999) Malignant transformation of p53-deficient astrocytes is modulated by environmental cues in vitro. Cell Growth Differ 10: 73-86.
8. Chen J, Shi D, Liu X, Fang S, Zhang J, Zhao Y, (2012) Targeting SPARC by lentivirus-mediated RNA interference inhibits cervical cancer cell growth and metastasis. BMC Cancer 12: 464.
9. Fenouille N, Puissant A, Tichet M, Zimniak G, Abbe P, Mallavialle A, et al (2011) SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival. Oncogene 30: 4887-4900.
10. Fenouille N, Robert G, Tichet M, Puissant A, Dufies M, Rocchi S, et al (2011) The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression. Pigment Cell Melanoma Res 24: 219-232.
11. Galarneau H, Villeneuve J, Gowing G, Julien JP, Vallieres L, (2007) Increased glioma growth in mice depleted of macrophages. Cancer Res 67: 8874-8881.
12. Golembieski WA, Ge S, Nelson K, Mikkelsen T, Rempel SA, (1999) Increased SPARC expression promotes U87 glioblastoma invasion in vitro. Int J Dev Neurosci 17: 463-472.
13. Horie K, Tsuchihara M, Nakatsura T, (2010) Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G arrest induction. Cancer Sci 101: 913-919.
14. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC, Van Meir EG, (1999) Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9: 469-479.
15. Khwaja FW, Svoboda P, Reed M, Pohl J, Pyrzynska B, Van Meir EG, (2006) Proteomic identification of the wt-p53-regulated tumor cell secretome. Oncogene 25: 7650-7661.
16. Kock H, Harris MP, Anderson SC, Machemer T, Hancock W, Sutjipto S, et al (1996) Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int J Cancer 67: 808-815.
17. Kzhyshkowska J, Workman G, Cardo-Vila M, Arap W, Pasqualini R, Gratchev A, et al (2006) Novel function of alternatively activated macrophages: stabilin-1-mediated clearance of SPARC. J Immunol 176: 5825-5832.
18. Leung SY, Wong MP, Chung LP, Chan AS, Yuen ST, (1997) Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol 93: 518-527.
19. Menon PM, Gutierrez JA, Rempel SA, (2000) A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: high SPARC secretion correlates with decreased migration on vitronectin. Int J Oncol 17: 683-693.
20. Mora R, Abschuetz A, Kees T, Dokic I, Joschko N, Kleber S, et al (2009) TNF-alpha- and TRAIL-resistant glioma cells undergo autophagy-dependent cell death induced by activated microglia. Glia 57: 561-581.
21. Morantz RA, Wood GW, Foster M, Clark M, Gollahon K, (1979a) Macrophages in experimental and human brain tumors. Part 1: studies of the macrophage content of experimental rat brain tumors of varying immunogenicity. J Neurosurg 50: 298-304.
22. Morantz RA, Wood GW, Foster M, Clark M, Gollahon K, (1979b) Macrophages in experimental and human brain tumors. Part 2: studies of the macrophage content of human brain tumors. J Neurosurg 50: 305-311.
23. Noble M, Murray K, (1984) Purified astrocytes promote the in vitro division of a bipotential glial progenitor cell. EMBO J 3: 2243-2247.
24. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et al (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892-6899.
25. Ohgaki H, Kleihues P, (2011) Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 28: 177-183.
26. Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, et al (2004) Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108: 49-56.
27. Platten M, Kretz A, Naumann U, Aulwurm S, Egashira K, Isenmann S, Weller M, (2003) Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann Neurol 54: 388-392.
28. Puolakkainen PA, Brekken RA, Muneer S, Sage EH, (2004) Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res 2: 215-224.
29. Reifenberger J, Ring GU, Gies U, Cobbers L, Oberstrass J, An HX, et al (1996) Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 55: 822-831.
30. Rempel SA, Golembieski WA, Fisher JL, Maile M, Nakeff A, (2001) SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. J Neurooncol 53: 149-160.
31. Rempel SA, Golembieski WA, Ge S, Lemke N, Elisevich K, Mikkelsen T, Gutierrez JA, (1998) SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. J Neuropathol Exp Neurol 57: 1112-1121.
32. Said N, Frierson HF, Sanchez-Carbayo M, Brekken RA, Theodorescu D, (2013) Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J Clin Invest 123: 751-766.
33. Said N, Najwer I, Motamed K, (2007) Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. Am J Pathol 170: 1054-1063.
34. Said N, Socha MJ, Olearczyk JJ, Elmarakby AA, Imig JD, Motamed K, (2007) Normalization of the ovarian cancer microenvironment by SPARC. Mol Cancer Res 5: 1015-1030.
35. Said NA, Elmarakby AA, Imig JD, Fulton DJ, Motamed K, (2008) SPARC ameliorates ovarian cancer-associated inflammation. Neoplasia 10: 1092-1104.
36. Schultz C, Lemke N, Ge S, Golembieski WA, Rempel SA, (2002) Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res 62: 6270-6277.
37. Schultz CR, Golembieski WA, King DA, Brown SL, Brodie C, Rempel SA, (2012) Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival. Mol Cancer 11: 20.
38. Shi Q, Bao S, Maxwell JA, Reese ED, Friedman HS, Bigner DD, et al (2004) Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J Biol Chem 279: 52200-52209.
39. Shi Q, Bao S, Song L, Wu Q, Bigner DD, Hjelmeland AB, Rich JN, (2007) Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene 26: 4084-4094.
40. Thomas SL, Alam R, Lemke N, Schultz LR, Gutierrez JA, Rempel SA, (2010) PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling. Neuro-Oncol 12: 941-955.
41. Vadlamuri SV, Media J, Sankey SS, Nakeff A, Divine G, Rempel SA, (2003) SPARC affects glioma cell growth differently when grown on brain ECM proteins in vitro under standard versus reduced-serum stress conditions. Neuro-Oncol 5: 244-254.
42. Yahanda AM, Bruner JM, Donehower LA, Morrison RS, (1995) Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Mol Cell Biol 15: 4249-4259.
43. Yunker CK, Golembieski W, Lemke N, Schultz CR, Cazacu S, Brodie C, Rempel SA, (2008) SPARC-induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion. Int J Cancer 122: 2735-2743.
44. Zhai H, Heppner FL, Tsirka SE, (2011) Microglia/macrophages promote glioma progression. Glia 59: 472-485.